多巴胺β-基酶抑制对压力过载引起的右心室衰竭的影响
Stine Andersen1,2, Julie Sørensen Axelsen1,2, Anders H Nielsen-Kudsk1,2
1Department of Cardiology Aarhus University Hospital Aarhus Denmark.
Pulmonary circulation
|November 14, 2024
概括
用BIA 21-5337抑制多巴胺β-基酶 (DβH) 并没有改善右心室 (RV) 功能或肺高血压小鼠的重塑. 治疗降低了DβH活性,但对VR衰竭进展没有有益或有害影响.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 生理学 生理学 生理学
背景情况:
- 交感神经系统的激活与肺动脉高血压 (PAH) 有关.
- 多巴胺β-基酶 (DβH) 促进多巴胺转化为上腺素,这是交感神经传递的一个关键步骤.
- 了解DβH在右心室 (RV) 衰竭中的作用对于开发向疗法至关重要.
研究的目的:
- 为了研究使用BIA 21-5337在压力过载引起的RV故障中抑制DβH的治疗潜力.
- 评估BIA 21-5337对VR功能,重塑和相关生理标志物的影响.
主要方法:
- 在Wistar大鼠中,通过肺干带 (PTB) 诱导右心室衰竭.
- 治疗PTB大鼠的治疗方法是用BIA 21-5337或载体治疗,用 ivabradine组控制心率.
- 使用心声学,MRI和压力-体积循环评估了RV功能和重塑;测量了DβH活性和尿路的诺亚上腺素.
主要成果:
- PTB显著增加了RV后负载,导致RV功能障碍,重建和故障.
- 治疗BIA 21-5337成功降低了上腺DβH活性和尿中的诺阿德林水平.
- 在BIA 21-5337和车辆治疗组之间没有观察到VR功能或改造的显著差异.
结论:
- 在这个临床前模型中,用BIA 21-5337抑制多巴胺β-基酶并没有改变RV衰竭的进展.
- 尽管取得了预期的药理效果 (降低了DβH活性),但BIA 21-5337对VR重塑或功能既没有有益影响,也没有不利影响.
- 可能需要进一步的研究来探索其他DβH抑制剂或VR失败的治疗点.
更多相关视频
04:49Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
Published on: June 14, 2024
612
09:40Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
10.5K
相关概念视频
01:22Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
01:20Mitral Regurgitation I: Introduction
4
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
4
01:22Mitral Stenosis I: Introduction
2
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
2
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391